Associated Papers
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
39774325 (PubMed )
Supplement: 41588_2024_2039_MOESM5_ESM.xlsx › SuppFig6
Direct measurement of engineered cancer mutations and their transcriptional phenotypes in single cells.
Kim HS et al.
Nature Biotechnology, 2024
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
39140857 (PubMed )
Supplement: table_s1_bbae400.xlsx › Sheet1
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing.
Kostecka A et al.
Npj Breast Cancer, 2022
35768433 (PubMed )
Supplement: 41523_2022_443_MOESM9_ESM.xlsx › DuplexSeq_all
Hsp70- and Hsp90-Mediated Regulation of the Conformation of p53 DNA Binding Domain and p53 Cancer Variants.
Boysen M et al.
Molecular Cell, 2019
The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer.
Ishimine M et al.
Disease Markers, 2018
29651325 (PubMed )
Supplement: 5280736.f1.pdf
Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.
Ward DG et al.
Plos One, 2016
26901314 (PubMed )
Supplement: pone.0149756.s006.xlsx › Sheet1
HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A et al.
Experimental and Molecular Pathology, 2013
PES inhibits human-inducible Hsp70 by covalent targeting of cysteine residues in the substrate-binding domain.
Yang J et al.
The Journal of Biological Chemistry, 0
Select a paper to view details